| Trial ID: | L0846 |
| Source ID: | NCT02933450
|
| Associated Drug: |
Patiromer 25.2 G
|
| Title: |
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02933450/results
|
| Conditions: |
Kidney Failure, Chronic
|
| Interventions: |
DRUG: Patiromer 25.2 g
|
| Outcome Measures: |
Primary: Efficacy of Patiromer in Reducing Serum Potassium, serial serum potassium levels will be graphed and compared between the 2 groups, 6 hours | Secondary: Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting., adverse events will be recorded and compared between the 2 groups, 6 hours
|
| Sponsor/Collaborators: |
Sponsor: Baylor College of Medicine | Collaborators: Relypsa, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-08
|
| Completion Date: |
2017-08
|
| Results First Posted: |
2019-05-09
|
| Last Update Posted: |
2019-05-09
|
| Locations: |
Ben Taub Hospital, Houston, Texas, 77030, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02933450
|
